ArticleAnnals of nuclear medicine2022
Article in Annals of nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- FDG-PET/CT SUVmax Predicts Recurrence Risk of Resected Pleuropulmonary Solitary Fibrous Tumors.JTO clinical and research reports · 2026Article
- Positron emission tomography/computed tomography in risk-factor-negative young female with malignant pleural mesothelioma: A case report and review of literature.World journal of clinical cases · 2025Article
- Article
- Application ofFrontiers in medicine · 2025Article
- Case report: A case of giant malignant solitary fibrous tumor of the pleura with Doege-Potter's syndrome and review of the literature.Frontiers in oncology · 2024Article
- Addressing recurrent hypoglycaemia through thoracic surgical intervention: understanding Doege-Potter syndrome, a rarity in syndromes.Archives of medical sciences. Atherosclerotic diseases · 2024Article
- Surgery for Solitary Fibrous Tumors of the Pleura: A Review of the Available Evidence.Cancers · 2023Review
- Article
- Ga68-FAPI Imaging and Lu177-FAPI Therapy in a Case of Metastatic Solitary Fibrous Tumor.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo date, published studies have shown that
methodsFrom January 2016 to November 2021, we performed a retrospective review in 32 SFTPs patients who underwent
resultsThirty-two patients with SFTP were consecutively identified. The malignant SFTPs have higher Ki-67 expression (P = 0.005). The study observed that tumour heterogeneity without contrast injection (P = 0.001) and intratumor blood vessels (P = 0.047) were morphological features associated with malignant SFTP. Malignant SFTP was more frequently observed with higher SUVmax values (P = 0.001), higher SUVmean values (P = 0.001), higher TLG values (P = 0.006), and higher SULmax values (P < 0.001). For predicting malignant SFTP, the AUC values of SUVmax, SUVmean, TLG, and SULmax obtained by the area under curve analysis were 0.970 (95% CI 0.907-1.000; P = 0.001), 0.874 (95% CI 0.675-1.000; P = 0.009), 0.807 (95% CI 0.654-0.961; P = 0.031), and 0.911 (95% CI 0.747-1.000; P = 0.004), respectively.
conclusionThe study showed that metabolic and morphological features were useful for distinguishing malignant from benign SFTPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.